These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 22283751)
1. Selective activation of muscarinic acetylcholine receptors for the treatment of schizophrenia. Dean B Curr Pharm Biotechnol; 2012 Jun; 13(8):1563-71. PubMed ID: 22283751 [TBL] [Abstract][Full Text] [Related]
3. Muscarinic M1 and M4 receptors: Hypothesis driven drug development for schizophrenia. Dean B; Scarr E Psychiatry Res; 2020 Jun; 288():112989. PubMed ID: 32315882 [TBL] [Abstract][Full Text] [Related]
4. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Conn PJ; Jones CK; Lindsley CW Trends Pharmacol Sci; 2009 Mar; 30(3):148-55. PubMed ID: 19201489 [TBL] [Abstract][Full Text] [Related]
8. Muscarinic agonists and antagonists in schizophrenia: recent therapeutic advances and future directions. Bolbecker AR; Shekhar A Handb Exp Pharmacol; 2012; (208):167-90. PubMed ID: 22222699 [TBL] [Abstract][Full Text] [Related]
9. Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal. Dean B Expert Opin Investig Drugs; 2023; 32(12):1113-1121. PubMed ID: 37994870 [TBL] [Abstract][Full Text] [Related]
10. Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders. Teal LB; Gould RW; Felts AS; Jones CK Adv Pharmacol; 2019; 86():153-196. PubMed ID: 31378251 [TBL] [Abstract][Full Text] [Related]
11. Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia. Paul SM; Yohn SE; Popiolek M; Miller AC; Felder CC Am J Psychiatry; 2022 Sep; 179(9):611-627. PubMed ID: 35758639 [TBL] [Abstract][Full Text] [Related]
13. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. Mirza NR; Peters D; Sparks RG CNS Drug Rev; 2003; 9(2):159-86. PubMed ID: 12847557 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of TAK-071, a muscarinic M Kurimoto E; Yamada R; Hirakawa T; Kimura H Neurosci Lett; 2021 Nov; 764():136240. PubMed ID: 34509568 [TBL] [Abstract][Full Text] [Related]
15. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Friedman JI Psychopharmacology (Berl); 2004 Jun; 174(1):45-53. PubMed ID: 15205878 [TBL] [Abstract][Full Text] [Related]
16. Muscarinic agonists for the treatment of cognition in schizophrenia. Sellin AK; Shad M; Tamminga C CNS Spectr; 2008 Nov; 13(11):985-96. PubMed ID: 19037177 [TBL] [Abstract][Full Text] [Related]
17. Muscarinic receptor pharmacology and circuitry for the modulation of cognition. Bubser M; Byun N; Wood MR; Jones CK Handb Exp Pharmacol; 2012; (208):121-66. PubMed ID: 22222698 [TBL] [Abstract][Full Text] [Related]
18. Muscarinic receptors as a target for drugs treating schizophrenia. Bymaster FP; Felder C; Ahmed S; McKinzie D Curr Drug Targets CNS Neurol Disord; 2002 Apr; 1(2):163-81. PubMed ID: 12769625 [TBL] [Abstract][Full Text] [Related]
19. Simultaneous activation of muscarinic and GABA Cieślik P; Woźniak M; Tokarski K; Kusek M; Pilc A; Płoska A; Radulska A; Pelikant-Małecka I; Żołnowska B; Sławiński J; Kalinowski L; Wierońska JM Behav Brain Res; 2019 Feb; 359():671-685. PubMed ID: 30267715 [TBL] [Abstract][Full Text] [Related]